Unlocking the Potential of Platelet-Activating Factor Acetylhydrolase (PAFAH1B1) as a Drug Target

Target Name: PAFAH1B1

NCBI ID: G5048

PAFAH1B1

Unlocking the Potential of Platelet-Activating Factor Acetylhydrolase (PAFAH1B1) as a Drug Target

Platelet-activating factor acetylhydrolase (PAFAH1B1) is a key enzyme involved in the regulation of platelet function and plays a crucial role in the assembly and activation of platelets. This enzyme is isoform 1B of the PAFAH1 family, which is known to be involved in various cellular processes, including blood clotting, inflammation, and tissue repair. The deregulation of PAFAH1B1 has been implicated in the development of various diseases, including thrombosis, cancer, and neurodegenerative disorders. As a result, targeting this enzyme has become an attractive research focus in the field of pharmacology.

Drugs that Target PAFAH1B1: currently available drugs and in development

1. currently available drugs:

2. In development:

PAFAH1B1 has been identified as a potential drug target and has been the focus of various research studies aimed at understanding its function and developing new therapeutic approaches. One of the existing drugs that targets PAFAH1B1 is tasigna (IMGN 3022), which is a small interfering RNA (siRNA) drug designed to reduce the levels of PAFAH1B1 in cancer cells. Another drug that is currently in development is pevonedistat, a NEDD8-activating enzyme inhibitor, which has been shown to reduce the levels of PAFAH1B1 in cancer cells and improve the efficacy of anti-cancer drugs.

The potential benefits of targeting PAFAH1B1:

1. The prevention of thrombosis:

Thrombosis is a serious medical condition that can lead to serious complications, including death. The development of new treatments for thrombosis depends on the identification of potential drug targets. By targeting PAFAH1B1, researchers hope to develop new treatments that can prevent the formation of blood clots and improve patient outcomes.

2. The treatment of cancer:

Cancer is a leading cause of death worldwide, and its progression is a major challenge in the treatment of this disease. The deregulation of PAFAH1B1 has been implicated in the development and progression of various types of cancer. Targeting PAFAH1B1 could lead to the development of new therapeutic approaches for cancer treatment, including inhibitors of PAFAH1B1-mediated signaling pathways.

3. The treatment of neurodegenerative disorders:

Neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, are progressive neurological conditions that can lead to the loss of cognitive and motor function. The deregulation of PAFAH1B1 has been implicated in the development and progression of these disorders. Targeting PAFAH1B1 could lead to the development of new therapeutic approaches for neurodegenerative disorders.

Conclusion

In conclusion, PAFAH1B1 is a protein that plays a crucial role in various cellular processes, including blood clotting, inflammation, and tissue repair. The deregulation of PAFAH1B1 has been implicated in the development of various diseases, including thrombosis, cancer, and neurodegenerative disorders. Developing drugs that target PAFAH1B1 has the potential to improve patient outcomes and advance our understanding of this protein's role in disease. Ongoing research is focused on understanding the full potential of PAFAH1B1 as a drug target and developing new therapeutic approaches that can benefit patients.

Protein Name: Platelet Activating Factor Acetylhydrolase 1b Regulatory Subunit 1

Functions: Regulatory subunit (beta subunit) of the cytosolic type I platelet-activating factor (PAF) acetylhydrolase (PAF-AH (I)), an enzyme that catalyzes the hydrolyze of the acetyl group at the sn-2 position of PAF and its analogs and participates in PAF inactivation. Regulates the PAF-AH (I) activity in a catalytic dimer composition-dependent manner (By similarity). Required for proper activation of Rho GTPases and actin polymerization at the leading edge of locomoting cerebellar neurons and postmigratory hippocampal neurons in response to calcium influx triggered via NMDA receptors (By similarity). Positively regulates the activity of the minus-end directed microtubule motor protein dynein. May enhance dynein-mediated microtubule sliding by targeting dynein to the microtubule plus end. Required for several dynein- and microtubule-dependent processes such as the maintenance of Golgi integrity, the peripheral transport of microtubule fragments and the coupling of the nucleus and centrosome. Required during brain development for the proliferation of neuronal precursors and the migration of newly formed neurons from the ventricular/subventricular zone toward the cortical plate. Neuronal migration involves a process called nucleokinesis, whereby migrating cells extend an anterior process into which the nucleus subsequently translocates. During nucleokinesis dynein at the nuclear surface may translocate the nucleus towards the centrosome by exerting force on centrosomal microtubules. May also play a role in other forms of cell locomotion including the migration of fibroblasts during wound healing. Required for dynein recruitment to microtubule plus ends and BICD2-bound cargos (PubMed:22956769). May modulate the Reelin pathway through interaction of the PAF-AH (I) catalytic dimer with VLDLR (By similarity)

The "PAFAH1B1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PAFAH1B1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets